Show simple item record

dc.contributor.authorQuindós, Guillermo
dc.contributor.authorMiranda-Cadena, Katherine
dc.contributor.authorSan-Millán, Rosario
dc.contributor.authorBorroto-Esoda, Katyna
dc.contributor.authorCantón, Emilia
dc.contributor.authorLinares-Sicilia, María José
dc.contributor.authorHamprecht, Axel
dc.contributor.authorMontesinos, Isabel
dc.contributor.authorTortorano, Anna M.
dc.contributor.authorPrigitano, Anna
dc.contributor.authorVidal-García, Matxalen
dc.contributor.authorMarcos-Arias, Cristina
dc.contributor.authorGuridi, Andrea
dc.contributor.authorSánchez-Reus, Ferrán
dc.contributor.authorMachuca Bárcena, Jesús
dc.contributor.authorRodríguez Iglesias, Manuel Antonio 
dc.contributor.authorMartín-Mazuelos, Estrella
dc.contributor.authorCastro-Méndez, Carmen
dc.contributor.authorLópez-Soria, Leyre
dc.contributor.authorRuiz-Gaitán, Alba
dc.contributor.authorFernández-Rivero, Marcelo
dc.contributor.authorLorenzo, Damaris
dc.contributor.authorCapilla, Javier
dc.contributor.authorRezusta, Antonio
dc.contributor.authorPemán, Javier
dc.contributor.authorGuarro, Josep
dc.contributor.authorPereira, Joana
dc.contributor.authorPais, Célia
dc.contributor.authorRomeo, Orazio
dc.contributor.authorEzpeleta, Guillermo
dc.contributor.authorJauregizar, Nerea
dc.contributor.authorAngulo, David
dc.contributor.authorEraso, Elena
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2023-01-10T12:44:20Z
dc.date.available2023-01-10T12:44:20Z
dc.date.issued2022-05
dc.identifier.issn2235-2988
dc.identifier.urihttp://hdl.handle.net/10498/27708
dc.description.abstractBackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. MethodsIbrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. ResultsIbrexafungerp MICs ranged from 0.016 to >= 8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06->= 8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. ConclusionIbrexafungerp showed a potent in vitro activity against Candida.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherFRONTIERS MEDIA SAes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceFrontiers in Cellular and Infection Microbiology, Vol. 12es_ES
dc.subjectantifungal testinges_ES
dc.subjectantifungal resistancees_ES
dc.subjectCandidaes_ES
dc.subjectibrexafungerpes_ES
dc.subjectSCY-078es_ES
dc.subjectEUCASTes_ES
dc.subjectcaspofungines_ES
dc.subjectmicafungines_ES
dc.titleIn Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Studyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3389/fcimb.2022.906563


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional